Park Avenue Securities LLC Has $342,000 Position in Privia Health Group, Inc. (NASDAQ:PRVA)

Park Avenue Securities LLC lifted its stake in Privia Health Group, Inc. (NASDAQ:PRVA) by 3.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,229 shares of the company’s stock after purchasing an additional 532 shares during the period. Park Avenue Securities LLC’s holdings in Privia Health Group were worth $342,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Durable Capital Partners LP grew its holdings in Privia Health Group by 3.4% during the 4th quarter. Durable Capital Partners LP now owns 11,487,843 shares of the company’s stock worth $224,587,000 after acquiring an additional 378,255 shares during the period. Nuveen Asset Management LLC grew its holdings in Privia Health Group by 19.8% during the 4th quarter. Nuveen Asset Management LLC now owns 1,488,979 shares of the company’s stock worth $29,110,000 after acquiring an additional 246,393 shares during the period. Loomis Sayles & Co. L P grew its holdings in Privia Health Group by 55.0% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,418,234 shares of the company’s stock worth $27,727,000 after acquiring an additional 503,002 shares during the period. Dimensional Fund Advisors LP grew its holdings in Privia Health Group by 10.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,416,235 shares of the company’s stock worth $27,687,000 after acquiring an additional 138,747 shares during the period. Finally, Northern Trust Corp grew its holdings in Privia Health Group by 14.2% during the 4th quarter. Northern Trust Corp now owns 1,392,641 shares of the company’s stock worth $27,226,000 after acquiring an additional 173,563 shares during the period. Institutional investors and hedge funds own 94.48% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on PRVA shares. Barclays lifted their price target on shares of Privia Health Group from $23.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Tuesday, May 27th. Robert W. Baird boosted their price objective on shares of Privia Health Group from $24.00 to $26.00 and gave the company an “outperform” rating in a research report on Tuesday, April 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Privia Health Group in a research report on Thursday, April 10th. JPMorgan Chase & Co. boosted their price target on shares of Privia Health Group from $29.00 to $32.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 28th. Finally, Canaccord Genuity Group boosted their price objective on shares of Privia Health Group from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $27.77.

Privia Health Group Stock Performance

Shares of PRVA opened at $22.65 on Monday. Privia Health Group, Inc. has a 52 week low of $16.37 and a 52 week high of $26.09. The firm has a market cap of $2.76 billion, a P/E ratio of 226.52, a price-to-earnings-growth ratio of 3.47 and a beta of 0.83. The firm’s 50-day simple moving average is $23.46 and its 200 day simple moving average is $22.84.

Insider Buying and Selling at Privia Health Group

In other Privia Health Group news, CEO Parth Mehrotra sold 15,100 shares of the business’s stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total value of $352,283.00. Following the completion of the sale, the chief executive officer now owns 454,281 shares of the company’s stock, valued at $10,598,375.73. The trade was a 3.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO David Mountcastle sold 3,322 shares of the business’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $24.99, for a total transaction of $83,016.78. Following the completion of the sale, the chief financial officer now directly owns 172,909 shares of the company’s stock, valued at $4,320,995.91. This represents a 1.89% decrease in their position. The disclosure for this sale can be found here. Insiders sold 51,579 shares of company stock valued at $1,226,367 in the last quarter. Company insiders own 10.70% of the company’s stock.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.